CJC-1295 vs Tesamorelin
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and Tesamorelin (Egrifta). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Both are GHRH analogs. Only one is FDA approved, and that is the whole story. Tesamorelin (brand name Egrifta) was approved in 2010 for HIV-associated lipodystrophy and received a new formulation approval as Egrifta WR in 2025. Brand pricing is brutal - roughly $10,673 per month retail for the original - but compounded tesamorelin through legitimate clinical programs runs around $200 per month. CJC-1295 never got FDA approved. It hit Category 2 in September 2023 and sits on the February 2026 pending reclassification list, which means no compounding pharmacy can legally make it for you.
Structurally, both are longer-acting sermorelin variants. Tesamorelin has a trans-3-hexenoic acid stabilization at the N-terminus. CJC-1295 has four amino acid substitutions in its no-DAC form, or adds a maleimide-albumin binder for the DAC (week-long) form. Both survive enzymatic degradation longer than sermorelin, both produce larger and more sustained GH pulses. The key clinical difference is that tesamorelin has the only published indication for visceral fat reduction in a specific patient population (HIV lipodystrophy), while CJC-1295 has only limited peer-reviewed human data.
The regulatory gap is why cost comparisons are strange here. A brand tesamorelin script at $10,673 per month is vastly more expensive than research-grade CJC-1295 at $35-70 per month, but compounded tesamorelin through legitimate specialty pharmacies brings that down to around $200 per month - actually competitive with underground peptide channels, and with a legal prescription behind it. The table below breaks down mechanism, half-life, legal status, and real-world pricing for each compound.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | Tesamorelin Egrifta, TH9507 |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | FDA Approved |
| Category | Growth Hormone | Growth Hormone |
| Primary Use | Growth hormone optimization and anti-aging | HIV-associated lipodystrophy |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $200 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1-2mg twice weekly (with DAC) | 2mg daily |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | High |
| Clinical Trial Phase | N/A | Approved |
Key Differences
- 1Tesamorelin is FDA-approved, while CJC-1295 is currently category 2 (pending reclassification).
- 2CJC-1295 is generally more affordable ($35 - $70/mo) compared to Tesamorelin ($200 - $1,500/mo).
- 3CJC-1295 is dosed twice weekly, while Tesamorelin is daily.
- 4Tesamorelin has high-quality evidence, while CJC-1295 has emerging-quality evidence.
Which Is Better For...
Tesamorelin
Those seeking an FDA-approved treatment with established safety data
CJC-1295
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
CJC-1295
Fewer commonly reported side effects
Tesamorelin
Stronger clinical evidence base to support its use
Tesamorelin is the legitimate choice, and it is not close. It is FDA approved since 2010 (Egrifta), has published randomized controlled trial data showing visceral fat reduction in HIV lipodystrophy, got a new Egrifta WR formulation approved in 2025, and is available through legitimate compounding pharmacies for roughly $200 per month - actually cheaper than many research peptide suppliers. CJC-1295 is structurally similar and potentially more potent per dose on paper, but it is FDA Category 2 and unobtainable through any legal pharmacy pathway. Unless you are specifically running a research protocol, the answer here is tesamorelin through a clinic with a real prescription.
Get CJC-1295 or Tesamorelin Online
Vetted telehealth providers that prescribe either peptide.
PeptideVS may earn a commission from providers listed below. Our editorial data is independent - see our disclosure for details.
Eden
Sponsored
Research peptide telehealth covering recovery, longevity, and growth-hormone protocols.
- Non-GLP-1 peptide catalog (GHRH, healing, longevity)
- Licensed prescriber intake, US pharmacy fulfillment
- Multi-peptide stacks available
We may earn a commission when you sign up.
PlushCare
Sponsored
Primary-care telehealth with broad Rx coverage and same-day appointments.
- Broad primary-care scope, not GLP-1-only
- Same-day video visits in all 50 states
- Works with insurance for most plans
We may earn a commission when you sign up.
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Tesamorelin | $200 - $1,500/mo | FDA Approved | Theratechnologies |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Brand Egrifta runs about $10,673 per month retail because it was specifically developed and priced for HIV-associated lipodystrophy, a small patient population with insurance coverage through HIV treatment programs. The compounded version uses the same molecule but is produced by 503A pharmacies for roughly $200 per month through anti-aging and HRT clinics as an off-label prescription. Same compound, different supply chain, dramatically different price. Egrifta WR launched in 2025 as a new formulation at similar brand pricing.
Tesamorelin has the only randomized controlled trial data showing visceral adipose tissue reduction in humans, published as part of its FDA approval for HIV lipodystrophy. CJC-1295 has no comparable published data. That does not mean CJC-1295 does not work - the GHRH mechanism is shared - but the evidence-based answer is tesamorelin. If visceral fat reduction is your specific goal and you want data behind the choice, tesamorelin is the defensible pick.
Technically yes, but most primary care doctors will not. Off-label tesamorelin for adult anti-aging or visceral fat reduction in non-HIV patients requires a doctor comfortable with hormone optimization and peptide therapy. The realistic path is through an HRT clinic, anti-aging specialist, or telehealth provider in the peptide space. Expect an initial consult with blood work, then a monthly program. Pricing varies by clinic, usually landing in the $200-400 range for the full program.
Maybe. The February 2026 FDA announcement put CJC-1295 on a formal reclassification review list along with BPC-157, ipamorelin, and others. Possible outcomes range from restoring 503A compounding eligibility (best case) to keeping Category 2 restrictions to adding new controls. The review is expected to conclude within 12-18 months of the announcement, but there is no guarantee CJC-1295 will return to the legal compounding pathway. Tesamorelin is not affected by the review - it is FDA approved.
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. Tesamorelin works via Synthetic GHRH analog that reduces visceral adipose tissue by stimulating growth hormone. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while Tesamorelin costs $200 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). Tesamorelin is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of Tesamorelin include Injection site reactions, Arthralgia, Peripheral edema. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideTesamorelin is an FDA-approved synthetic growth hormone releasing hormone analog specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. A new weekly reco...
View Full Tesamorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and Tesamorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.